▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3512 by analyst upside · 2026-06-27
MRK
Merck & Co., Inc.
Healthcare · Market Cap $318B · P/E 35.3x
ANALYST PRICE TARGET
+1.3%
implied upside to consensus target
Current Price $128.66
Consensus Target $130.39
Bull Target $150.0
Bear Target $100.0
Analysts Covering 28
ANALYST CONSENSUS — BUY
Strong Buy
4
Buy
14
Hold
11
Sell
0
52-Week Low $76.66
52-Week High $128.78
YTD Return +22.6%
FUNDAMENTALS
Market Cap $318B
P/E Ratio (TTM) 35.3x
Forward P/E 13.5x
EPS (TTM) $3.64
PEG Ratio 5.61
Dividend Yield 2.71%
Revenue (TTM) $65.8B
Profit Margin 13.6%
52-WEEK RANGE
52-Week Low $76.66
52-Week High $128.78
Current Price $128.66
Bear Target $100.0
Bull Target $150.0
● Now $128.66 ● Target $130.39
TRADING DATA
Avg Volume 10.2M
YTD Return +22.6%
Analyst Count 28
Consensus Buy
Upside to Target +1.3%
Last Updated 2026-06-27

ANALYST SUMMARY

Merck & Co., Inc. (MRK) is currently trading at $128.66 with a Wall Street consensus price target of $130.39, implying potential upside of 1.3% over the next 12 months. 28 analysts currently cover MRK, with a consensus rating of Buy — 62% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $150.0, while the most cautious has a target of $100.0.

MRK operates in the Healthcare sector with a market capitalisation of $318B. The stock is up 22.6% year-to-date and is currently trading near the upper end of its 52-week range of $76.66 – $128.78.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

NVS -1.0%
Novartis AG
$297B · P/E 22.2x · Buy
UNH -3.9%
UnitedHealth Group Incorporated
$389B · P/E 32.2x · Buy
AZN +19.1%
AstraZeneca PLC
$292B · P/E 27.9x · Buy
NVO -2.5%
Novo Nordisk A/S
$213B · P/E 11.4x · Hold
AMGN -1.6%
Amgen Inc.
$193B · P/E 24.6x · Hold

RECENT ANALYST CALLS

Upgrade/downgrade history for MRK, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Wells Fargo — Reiterated
Overweight → Overweight 2026-05-01 Building track record
UBS — Reiterated
Buy → Buy 2026-04-13 33% win rate (6 calls)
JP Morgan — Reiterated
Overweight → Overweight 2026-04-06 43% win rate (7 calls)
RBC Capital reit
Outperform → Outperform 2026-03-30 Building track record
Citigroup — Reiterated
Neutral → Neutral 2026-03-20 Building track record
Wells Fargo — Reiterated
Overweight → Overweight 2026-03-12 Building track record
RBC Capital ● Initiated
Outperform 2026-02-25 Building track record
Barclays ● Initiated
Overweight 2026-02-20 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
—
out of 100
Coverage depth
0/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
0/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →